Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 (Eprenetapopt) and Azacitidine in Patients with TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia at the 25th European Hematology Association Annual Meeting
12 juin 2020 06h00 HE
|
Aprea Therapeutics
57% CR and 75% ORR rate by IWG criteria in all evaluable MDS patients 12.1 months median OS in intention-to-treat MDS patients with 9.7 months median duration of follow-up 13.7 months median OS...
Onconova Therapeutics Announces Presentation at BIO Digital 2020
08 juin 2020 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., June 08, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat...
Aprea Therapeutics Completes Full Enrollment of Phase 3 Clinical Trial in TP53 Mutant Myelodysplastic Syndromes (MDS)
03 juin 2020 08h00 HE
|
Aprea Therapeutics
Topline data expected by year-end 2020Applications for US and EU regulatory approval planned for 2021 BOSTON, June 03, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a...
Geron Corporation Reports First Quarter 2020 Financial Results
28 mai 2020 16h05 HE
|
Geron Corporation
MENLO PARK, Calif., May 28, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the first quarter ended March 31, 2020. The Company will host a conference...
Geron Corporation Announces the Closing of its Public Offering of Common Stock and Warrants
27 mai 2020 16h30 HE
|
Geron Corporation
MENLO PARK, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the closing of its previously announced...
FibroGen to Present at Upcoming Investor Conferences
27 mai 2020 07h00 HE
|
FibroGen, Inc
SAN FRANCISCO, May 27, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following...
Geron Corporation Announces the Pricing of its Public Offering of Common Stock and Warrants
22 mai 2020 07h15 HE
|
Geron Corporation
MENLO PARK, Calif., May 22, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of its previously announced...
Geron Corporation Announces Proposed Public Offering of Common Stock and Warrants
21 mai 2020 16h03 HE
|
Geron Corporation
MENLO PARK, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it intends to offer and sell shares of...
Geron Announces Plans for Imetelstat Phase 3 Clinical Trial in Myelofibrosis and Other Updates
21 mai 2020 16h01 HE
|
Geron Corporation
Geron plans to move forward with a Phase 3 clinical trial in refractory myelofibrosis (MF) with overall survival (OS) as a primary endpoint, which is expected to open for screening and enrollment in...
Onconova Therapeutics Provides Corporate Update and Reports First Quarter 2020 Financial Results
14 mai 2020 16h05 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., May 14, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat...